BioAegis’ Patent Rights Extend to Applications for Inflammation

Recombinant plasma gelsolin has been shown to be a biomarker of inflammation in a wide range of diseases and in particular in rheumatoid arthritis (RA). This abundant human plasma protein is expected to have utility in patients with RA, as well as other inflammatory diseases.


Plasma Gelsolin Could Hold the Key to the Body’s Ability to Localize Inflammation

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(May 17, 2011) BioAegis Therapeutics, Inc. announced today that it has entered into an Exclusive Option Agreement with Brigham and Women’s Hospital for technology based on research of Dr. Thomas Stossel, Director, Translational Medicine at Brigham and Women’s Hospital, and American Cancer Society Professor of Medicine, Harvard Medical School and collaborators at Massachusetts General Hospital, University of Pennsylvania, Beth Israel Deaconess Medical Center and BloodCenter of Wisconsin. This exclusive option to a worldwide license encompasses therapeutic and diagnostic uses of the technology for human and animal applications.